Completing both an MA and Ph.D. at the Hebrew University’s Department of Microbiology under the guidance of Professor Engelberg-Kulka. Their research has yielded several articles and reviews, two of which were published in Science magazine, focusing on identifying a novel programmed cell death pathway in E. coli.

After completing their Ph.D., he pursued a post-doctoral fellowship at the Hebrew University where he worked on two projects, plasmids of Fusobacterium nucleatum and quorum sensing of Bacillus subtillis. This research findings were published in three papers.

Undertook a post-doctoral fellowship at Harvard Medical School and Massachusetts General Hospital (MGH), working under the supervision of Professor Laurence. G. Rahme. Their research focused on bacterial cell-to-cell communication and cell-fate regulation in Pseudomonas aeruginosa, an opportunistic human pathogen. Their research yielded ten papers, a book chapter, and a case report.

In 2013, founded a lab at the Institute of Biomedical and Oral Research (IBOR), Faculty of Dental Medicine of the Hebrew University of Jerusalem.

The research in the Hazan lab focuses on phage biology, phage "hunting", induction of lysogens, phage "banking", phage engineering, interactions between phages and the immune system, RNA intra-cellular communication, and many others. They have numerous collaborations in Israel and worldwide and are well respected in the phage therapy community. Their lab has published 30 papers and reviewed and participated in 5 more.

Together with the collaborator, Prof. Ran Nir-Paz from the Department of Infectious diseases of Hadassah Medical Center (HMC), they established the Israeli Phage Therapy Center (IPTC), the first and only phage center which treated patients in Israel. The IPTC aims to conduct the most advanced personalized, dynamic, and adaptive medicine for infectious diseases. They trust this center will stand out among other international endeavors due to their unique process of tailoring the treatment for each patient, which is chosen and developed using both in-vitro assay customization guided by AI algorithms.

Since October 2022, he has been serving as the elected Head of IBOR. Their lab played a pioneering role in introducing phage therapy in Israel.

One of the major activities of the IPTC is isolating and characterizing numerous phages against many bacterial targets to create a large "bank". Each isolated phage is also tested for synergy and antagonism with relevant antibiotic agents.